Hookipa Pharma (HOOK) has issued an announcement.
HOOKIPA Pharma Inc. has shared promising results from a Phase 2 clinical trial of their cancer treatment, HB-200, combined with pembrolizumab for patients with HPV16+ head and neck cancer. Demonstrating a favorable safety profile and encouraging clinical activity, the treatment showed significant positive responses in patients, especially those with higher PD-L1 levels. With no treatment-related deaths and a high overall survival rate, these findings mark a significant step forward and are accessible for further details on the company’s investor relations website.
See more insights into HOOK stock on TipRanks’ Stock Analysis page.
